The treatment by using rivastigmine for patients with Alzheimer disease: Results of a multicenter, randomized, open-labeled, controlled clinical trial

Chinese Journal of Neurology

Volumn 34, Issue 4, 2001, Pages 210-213

  Wang, Y ^a   Chen, Q ^a   Zhang, Z ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Clinical trials; Rivastigmine

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0035949219     PISSN: 10067876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Efficacy and safety of rivastigmine in patients with Alzheimer's disease, international randomised controlled trial
2. Chinical diagnosis of Alzheimer's disease: Report of the NINCDS/ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease
3. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
4. Changes in brain cholinesterases in senile dementia of Alzheimer's type
5. Clinical pharmacology of rivastigmine: A new-generation acetycholinesterate inhibition for the treatment of Alzheimer's disease
6. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
7. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
8. Cholinesterase inhibitors: A therepeutic strategy for Alzheimer's disease
9. Rivastigmine: A review of its use in Alzheimer's disease
10. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
11. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
12. Dose-dependent CSF acetycholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
13. Cholinesterase inhibitor in treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
14. Arandomized trial evaluating the efficacy and safety ENA, 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild moderately severe Alzheimer's disease
15. Systematic review of the efficiency of rivastimraine for patients with Alzheimer's disease
16. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
17. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease